Ebola Drug Approved by FDA
Latest Infectious Disease News
THURSDAY, Oct. 15, 2020 (HealthDay News) — A new drug to treat Ebola was approved by the U.S. Food and Drug Administration on Wednesday.
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) is a mixture of three monoclonal antibodies, and the first FDA-approved treatment for Ebola virus infection in adults and children.
The drug was tested in one clinical trial that included 382 adults and children with Ebola in the Democratic Republic of the Congo during an Ebola virus outbreak in 2018-2019.
The death rate after 28 days was 33.8% among the 154 patients who received Inmazeb, compared to 51% of those who received an experimental control drug.
Copyright © 2019 HealthDay. All rights reserved.
Source link